Co-Diagnostics, Inc. and CoSara to Host HPV and Cancer Symposium on International HPV Day 2025
Co-Diagnostics (CODX) and CoSara Diagnostics announced they will host a symposium titled 'HPV and Cancer: Exploring Advances in Prevention and Care' on March 4, 2025, in Baroda, India, coinciding with International HPV Awareness Day. The event will feature speakers from both companies and cancer experts from across India.
The symposium comes as CODX completes development of its HPV multiplex test on the Co-Dx PCR point-of-care platform, designed to identify 8 high-risk HPV subtypes from cervical swab samples. This development aims to provide affordable HPV screening, particularly in low and middle-income countries, where according to WHO, 94% of the 350,000 cervical cancer deaths in 2022 occurred.
CoSara's Saragene® Human Papillomavirus-High Risk real-time PCR test has already received Indian CDSCO clearance for detecting HPV high-risk genotypes 16 and 18. The National Cancer Institute reports that high-risk HPV subtypes cause approximately 5% of all cancers worldwide, with cervical cancer being the fourth most common cancer in women.
Co-Diagnostics (CODX) e CoSara Diagnostics hanno annunciato che ospiteranno un simposio intitolato 'HPV e Cancro: Esplorare i Progressi nella Prevenzione e nella Cura' il 4 marzo 2025 a Baroda, India, in coincidenza con la Giornata Internazionale di Sensibilizzazione sull'HPV. L'evento presenterà relatori di entrambe le aziende e esperti di cancro provenienti da tutta l'India.
Il simposio si svolge mentre CODX completa lo sviluppo del suo test multiplex HPV sulla piattaforma Co-Dx PCR point-of-care, progettato per identificare 8 sottotipi HPV ad alto rischio da campioni di tampone cervicale. Questo sviluppo mira a fornire uno screening HPV accessibile, in particolare nei paesi a basso e medio reddito, dove secondo l'OMS, il 94% delle 350.000 morti per cancro cervicale nel 2022 si è verificato.
Il test PCR in tempo reale Saragene® di CoSara per il Papillomavirus Umano ad Alto Rischio ha già ricevuto l'approvazione del CDSCO indiano per la rilevazione dei genotipi HPV ad alto rischio 16 e 18. L'Istituto Nazionale dei Tumori riporta che i sottotipi HPV ad alto rischio causano circa il 5% di tutti i tumori nel mondo, con il cancro cervicale che è il quarto tumore più comune tra le donne.
Co-Diagnostics (CODX) y CoSara Diagnostics anunciaron que organizarán un simposio titulado 'VPH y Cáncer: Explorando Avances en Prevención y Cuidado' el 4 de marzo de 2025 en Baroda, India, coincidiendo con el Día Internacional de Concienciación sobre el VPH. El evento contará con oradores de ambas empresas y expertos en cáncer de toda India.
El simposio se lleva a cabo mientras CODX completa el desarrollo de su prueba multiplex de VPH en la plataforma Co-Dx PCR point-of-care, diseñada para identificar 8 subtipos de VPH de alto riesgo a partir de muestras de hisopos cervicales. Este desarrollo tiene como objetivo proporcionar un cribado de VPH asequible, particularmente en países de ingresos bajos y medios, donde, según la OMS, el 94% de las 350,000 muertes por cáncer cervical en 2022 ocurrieron.
La prueba de PCR en tiempo real Saragene® de CoSara para el Papilomavirus Humano de Alto Riesgo ya ha recibido la aprobación del CDSCO indio para detectar los genotipos de VPH de alto riesgo 16 y 18. El Instituto Nacional del Cáncer informa que los subtipos de VPH de alto riesgo causan aproximadamente el 5% de todos los cánceres en el mundo, siendo el cáncer cervical el cuarto cáncer más común entre las mujeres.
코다이아그노스틱스 (CODX)와 코사라 다이아그노스틱스는 2025년 3월 4일 인도 바로다에서 'HPV와 암: 예방 및 치료의 발전 탐구'라는 제목의 심포지엄을 개최한다고 발표했습니다. 이 행사는 국제 HPV 인식의 날과 일치하며, 두 회사의 연사와 인도 전역의 암 전문가들이 참석할 예정입니다.
이 심포지엄은 CODX가 자궁경부 면봉 샘플에서 8개의 고위험 HPV 아형을 식별하도록 설계된 Co-Dx PCR 포인트 오브 케어 플랫폼에서 HPV 멀티플렉스 테스트 개발을 완료하는 시점에 열립니다. 이 개발은 WHO에 따르면 2022년 350,000명의 자궁경부암 사망자의 94%가 발생한 저소득 및 중간 소득 국가에서 저렴한 HPV 선별 검사를 제공하는 것을 목표로 합니다.
코사라의 Saragene® 인간 유두종 바이러스-고위험 실시간 PCR 테스트는 이미 고위험 유전자형 16과 18을 검출하기 위해 인도 CDSCO 승인을 받았습니다. 국립암연구소는 고위험 HPV 아형이 전 세계적으로 약 5%의 모든 암을 유발하며, 자궁경부암이 여성에게 가장 흔한 네 번째 암이라고 보고하고 있습니다.
Co-Diagnostics (CODX) et CoSara Diagnostics ont annoncé qu'ils organiseront un symposium intitulé 'VPH et Cancer : Explorer les Avancées en Prévention et Soins' le 4 mars 2025 à Baroda, en Inde, coïncidant avec la Journée Internationale de Sensibilisation au VPH. L'événement mettra en vedette des intervenants des deux entreprises ainsi que des experts en cancérologie de toute l'Inde.
Le symposium se tient alors que CODX termine le développement de son test multiplex VPH sur la plateforme Co-Dx PCR point-of-care, conçu pour identifier 8 sous-types de VPH à haut risque à partir d'échantillons de prélèvements cervicaux. Ce développement vise à fournir un dépistage du VPH abordable, en particulier dans les pays à faible et moyen revenu, où selon l'OMS, 94 % des 350 000 décès par cancer du col de l'utérus en 2022 ont eu lieu.
Le test PCR en temps réel Saragene® de CoSara pour le Papillomavirus Humain à Haut Risque a déjà reçu l'approbation du CDSCO indien pour détecter les génotypes de VPH à haut risque 16 et 18. L'Institut National du Cancer rapporte que les sous-types de VPH à haut risque causent environ 5 % de tous les cancers dans le monde, le cancer du col de l'utérus étant le quatrième cancer le plus courant chez les femmes.
Co-Diagnostics (CODX) und CoSara Diagnostics haben angekündigt, dass sie am 4. März 2025 in Baroda, Indien, ein Symposium mit dem Titel 'HPV und Krebs: Fortschritte in Prävention und Pflege erkunden' veranstalten werden, das mit dem Internationalen HPV-Bewusstseinstag zusammenfällt. Die Veranstaltung wird Redner von beiden Unternehmen und Krebsexperten aus ganz Indien umfassen.
Das Symposium findet statt, während CODX die Entwicklung seines HPV-Multiplex-Tests auf der Co-Dx PCR Point-of-Care-Plattform abschließt, die darauf ausgelegt ist, 8 Hochrisiko-HPV-Subtypen aus Zervixabstrichproben zu identifizieren. Diese Entwicklung zielt darauf ab, kostengünstige HPV-Screenings anzubieten, insbesondere in einkommensschwachen und mittleren Ländern, wo laut WHO 94% der 350.000 Todesfälle durch Gebärmutterhalskrebs im Jahr 2022 stattfanden.
Der Saragene®-Test von CoSara für das humane Papillomavirus mit hohem Risiko hat bereits die Genehmigung des indischen CDSCO zur Erkennung der Hochrisiko-Genotypen 16 und 18 erhalten. Das Nationale Krebsinstitut berichtet, dass Hochrisiko-HPV-Subtypen etwa 5% aller Krebsfälle weltweit verursachen, wobei Gebärmutterhalskrebs die vierthäufigste Krebsart bei Frauen ist.
- None.
- None.
The symposium exploring advances in cancer prevention and care is set to take place on March 4, International HPV Awareness Day, in Baroda,
Titled "HPV and Cancer: Exploring Advances in Prevention and Care," the one-day symposium will take place on Tuesday, March 4, 2025 in Baroda,
The National Cancer Institute estimates that high-risk HPV subtypes cause roughly
The symposium comes as Co-Dx completes the assay development stage for its HPV multiplex test on the Co-Dx PCR point-of-care platform* in preparation for pre-clinical and pre-analytical studies. The test is designed to utilize Co-Dx Co-Primers® technology and the unique architecture of the Co-Dx PCR Pro instrument to identify 8 high-risk HPV subtypes from cervical swab samples, with the goal of providing an affordable, accessible HPV screening tool for patients around the world, especially in LMICs.
"Early diagnosis of illnesses can not only lead to earlier, more effective treatments and trigger patients to begin regular cervical cancer screenings, it can also form a vital component in limiting the spread of viruses like HPV," commented Dwight Egan CEO of Co-Dx. "We are pleased with the progress we have made on the HPV multiplex test and the preliminary performance data seen so far, and we are honored to participate with our joint venture partner in this symposium to raise awareness of this important health concern."
CoSara CEO Mohal Sarabhai added "In alignment with the missions of the joint venture partners, CoSara is committed to a world with increased access to high-quality infectious disease diagnostics. We believe that providing a forum for leading experts in fields like HPV and cancer to share knowledge with other researchers, physicians, oncologists and industry leaders advances the cause of disease prevention and global health."
CoSara's Saragene® Human Papillomavirus-High Risk real-time PCR test has been cleared by the Indian CDSCO for use as an IVD in clinical laboratories in
*The Co-Dx PCR platform (including the PCR Home™, PCR Pro™, mobile app, and all associated tests) is subject to review by the FDA and/or other regulatory bodies and is not yet available for sale.
About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a
Forward-Looking Statements:
This press release contains forward-looking statements. Forward-looking statements can be identified by words such as "believes," "expects," "estimates," "intends," "may," "plans," "will" and similar expressions, or the negative of these words. Forward-looking statements include statements made with respect to our Co-Dx PCR platform and the development of an HPV multiplex test. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. Forward-looking statements are subject to inherent uncertainties, risks and changes in circumstances. Actual results may differ materially from those contemplated or anticipated by such forward-looking statements. Readers of this press release are cautioned not to place undue reliance on any forward-looking statements. There can be no assurance that any of the anticipated results will occur on a timely basis or at all due to certain risks and uncertainties, a discussion of which can be found in our Risk Factors disclosure in our Annual Report on Form 10-K, filed with the Securities and Exchange Commission (SEC) on March 14, 2024, and in our other filings with the SEC. The Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws.
Please note that we disclaim any responsibility for the content of external links provided in this press release. These links are provided solely for the reader's convenience and do not constitute an endorsement by the Company.
View original content to download multimedia:https://www.prnewswire.com/news-releases/co-diagnostics-inc-and-cosara-to-host-hpv-and-cancer-symposium-on-international-hpv-day-2025-302389836.html
SOURCE Co-Diagnostics